Cullinan Therapeutics, Inc.
CGEM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $18,943 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $306 | $0 | $0 | $0 |
| Gross Profit | -$306 | $0 | $0 | $18,943 |
| % Margin | – | – | – | 100% |
| R&D Expenses | $142,903 | $148,156 | $91,948 | $57,751 |
| G&A Expenses | $52,816 | $42,493 | $40,189 | $29,146 |
| SG&A Expenses | $53,710 | $42,493 | $40,189 | $29,146 |
| Sales & Mktg Exp. | $894 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $440 | -$276,785 | $0 |
| Operating Expenses | $196,613 | $191,089 | -$144,648 | $86,897 |
| Operating Income | -$196,919 | -$191,089 | $144,648 | -$67,954 |
| % Margin | – | – | – | -358.7% |
| Other Income/Exp. Net | $29,461 | $21,866 | $6,668 | $469 |
| Pre-Tax Income | -$167,458 | -$169,223 | $151,316 | -$67,485 |
| Tax Expense | $117 | -$14,122 | $42,121 | $0 |
| Net Income | -$167,383 | -$153,162 | $111,214 | -$65,570 |
| % Margin | – | – | – | -346.1% |
| EPS | -3.11 | -3.69 | 2.46 | -1.48 |
| % Growth | 15.7% | -250% | 266.2% | – |
| EPS Diluted | -3.11 | -3.69 | 2.38 | -1.48 |
| Weighted Avg Shares Out | 53,771 | 41,507 | 45,164 | 44,292 |
| Weighted Avg Shares Out Dil | 53,771 | 41,550 | 46,640 | 44,292 |
| Supplemental Information | – | – | – | – |
| Interest Income | $29,660 | $21,627 | $6,611 | $477 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $306 | $310 | $93 | $53 |
| EBITDA | -$167,152 | -$190,339 | -$132,044 | -$67,901 |
| % Margin | – | – | – | -358.4% |